phase 2: 1)The donors :Healthy male or female aged 18-60 years; inoculated with specific H1N1 vaccine; titer of H1N1 hemagglutination inhibition antibody must be 1:80 or more than after examination (the kit shall be provided by the WHO) by Shanghai Municipal Center for Disease Control and Prevention 2)The patients: clinical H1N1patients with positive swab nucleic acid Real-time PCR test; critical H1N1 patients;fever less than 10 days;virus viremia was Preferred [clinicaltrials_resource:ce8b1d98e5c705dc859318dbc05fad47]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
phase 2: 1)The donors :Healthy male or female aged 18-60 years; inoculated with specific H1N1 vaccine; titer of H1N1 hemagglutination inhibition antibody must be 1:80 or more than after examination (the kit shall be provided by the WHO) by Shanghai Municipal Center for Disease Control and Prevention 2)The patients: clinical H1N1patients with positive swab nucleic acid Real-time PCR test; critical H1N1 patients;fever less than 10 days;virus viremia was Preferred [clinicaltrials_resource:ce8b1d98e5c705dc859318dbc05fad47]
Bio2RDF identifier
ce8b1d98e5c705dc859318dbc05fad47
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ce8b1d98e5c705dc859318dbc05fad47
identifier
clinicaltrials_resource:ce8b1d98e5c705dc859318dbc05fad47
title
phase 2:
1)The do ...... ys;virus viremia was Preferred
@en
type
label
phase 2:
1)The do ...... b1d98e5c705dc859318dbc05fad47]
@en